An estimated right ventricular systolic pressure > 30 mmHg predicted a two-fold higher all-cause mortality compared to ≤ 30 mmHg in patients with type 2 diabetes (51.4% vs 29.1%; p<0.001).
Cohort (n=416)
Yes
Does elevated estimated right ventricular systolic pressure (eRVSP > 30 mmHg) predict increased all-cause mortality in patients with type 2 diabetes?
An estimated right ventricular systolic pressure > 30 mmHg on echocardiography is an independent predictor of two-fold higher all-cause mortality in patients with type 2 diabetes.
Effect estimate: two-fold higher
Absolute Event Rate: 51.4% vs 29.1%
p-value: p=<0.001
An elevated estimated right ventricular systolic pressure (eRVSP) identified on echocardiography is present in one-third of individuals with type 2 diabetes, but its prognostic significance is unknown. To assess the relationship between eRVSP and mortality, prospective data from 1732 participants in the Fremantle Diabetes Study Phase II were linked with the National Echocardiographic Database of Australia. Of this cohort, 416 (mean age 70.6 years, 47.4% males) had an eRVSP measured and 381 (91.4%) had previously confirmed type 2 diabetes. Receiver- operating characteristic analysis of the relationship between eRVSP and all-cause mortality was conducted. Survival analyses were performed for participants with type 2 diabetes diagnosed before first measured eRVSP (n = 349). Cox regression identified clinical and echocardiographic associates of all-cause mortality. There were 141 deaths (40.4%) during 2348 person-years (mean ± SD 6.7 ± 4.0 years) of follow-up. In unadjusted Kaplan–Meier analysis, mortality rose with higher eRVSP (log-rank test, p 30 to 35, >35 to 40, and >40 mmHg had significantly increased mortality compared with eRVSP ≤ 30 mmHg (p = 0.025, p = 0.001, p 30 mmHg (log-rank test, p 30 mmHg predicted a two-fold higher all-cause mortality versus ≤ 30 mmHg. An eRVSP > 30 mmHg predicts increased all-cause mortality in type 2 diabetes. Where available, eRVSP could inform type 2 diabetes outcome models.
Nundlall et al. (Thu,) conducted a cohort in Type 2 Diabetes (n=416). Estimated right ventricular systolic pressure (eRVSP) > 30 mmHg vs. eRVSP ≤ 30 mmHg was evaluated on All-cause mortality (two-fold higher, p=<0.001). An estimated right ventricular systolic pressure > 30 mmHg predicted a two-fold higher all-cause mortality compared to ≤ 30 mmHg in patients with type 2 diabetes (51.4% vs 29.1%; p<0.001).